Your session is about to expire
← Back to Search
Behavioural Intervention
Pathways Intervention for Autism
N/A
Waitlist Available
Led By Pamela R Rollins, Ed.D
Research Sponsored by The University of Texas at Dallas
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
are between 12-42 months old at the start of the study;
have no other known neurological or genetic concerns or disorders;
Timeline
Screening 3 weeks
Treatment Varies
Follow Up assessed for changes from baseline to 24 weeks and from 24-to-36 weeks
Awards & highlights
No Placebo-Only Group
Summary
This trial compares two programs for young children with autism. One program trains parents to help their kids develop social and communication skills, while the other provides parents with information about autism. The study aims to see which program is more effective in improving children's skills and reducing parental stress.
Who is the study for?
This trial is for families in Dallas, Texas with children aged 12-42 months who are diagnosed with or suspected of having autism. Participants must speak English or Spanish at home and have no other neurological or genetic disorders. The child's autism diagnosis needs to be confirmed by a specific test called ADOS-2.
What is being tested?
The study compares two interventions: Pathways, which involves parents in early autism intervention, and PEI, focused on parent education. It aims to see if Pathways improves social attention and language skills more effectively than PEI and reduces parental stress over a 24-week period.
What are the potential side effects?
Since this trial focuses on educational interventions rather than medications, traditional side effects are not applicable. However, there may be varying levels of stress or emotional impact associated with the intensity of the programs on both children and their parents.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My child is between 1 and 3.5 years old.
Select...
I do not have any known neurological or genetic disorders.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ assessed for changes from baseline to 24 weeks and from 24-to-36 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~assessed for changes from baseline to 24 weeks and from 24-to-36 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in child language
Change in child social communication
Changes in child Joint attention
+2 moreSecondary study objectives
Changes in parenting stress
changes in child adaptive functioning
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Pathways InterventionExperimental Treatment1 Intervention
Twenty-four weeks of a manualized Naturalistic Developmental Behavioral Intervention (NDBI) parent-mediated early autism intervention that uses a coaching model.
Group II: Parent Education Intervention (PEI)Active Control1 Intervention
Twenty-four weeks of individual caregiver training without the child being present.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Parent-mediated early interventions for Autism, such as the Pathways program, work by training parents to use targeted strategies to enhance their child's social orienting, joint attention, social communication, and language development during daily interactions. These interventions leverage the natural parent-child relationship to create a consistent and supportive learning environment, leading to meaningful improvements in the child's abilities.
Additionally, reducing parental stress through these programs is essential as it fosters a more stable and nurturing family dynamic, which is beneficial for the child's overall development.
Novel treatments in autism spectrum disorder.Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis.Parent-mediated early intervention for young children with autism spectrum disorders (ASD).
Novel treatments in autism spectrum disorder.Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis.Parent-mediated early intervention for young children with autism spectrum disorders (ASD).
Find a Location
Who is running the clinical trial?
The University of Texas at DallasLead Sponsor
64 Previous Clinical Trials
106,694 Total Patients Enrolled
Pamela R Rollins, Ed.DPrincipal InvestigatorUniversity of Texas at Dallas
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You do not meet the requirements to participate in the study.My primary home language is either English or Spanish.I am a caregiver with a child aged 12-42 months.You have been diagnosed with autism or there is a suspicion that you have it.You have been diagnosed with or are suspected of having autism.You are a student at the University of Texas at Dallas.My child is between 1 and 3.5 years old.I do not have any known neurological or genetic disorders.I do not have any known neurological or genetic disorders.
Research Study Groups:
This trial has the following groups:- Group 1: Parent Education Intervention (PEI)
- Group 2: Pathways Intervention
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.